Compare Avantis International Small Cap Value ETF (AVDV) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Avantis International Small Cap Value ETF trades at $109.58, while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). Which is the better fit depends on your goals.
| AVDV | BIO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $356.25 |
52-Week Low | $83.89 | $241.71 |
Market Cap | — | $9.39B |
Enterprise Value | — | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $109.63, up 1.34% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI. The stock has delivered strong returns recently, including a 35% gain highlighted in June 2026 news, and offers a dividend with a payment scheduled for June 2026. However, key valuation ratios such as P/E and P/B are unavailable, limiting fundamental clarity.
The outlook is mixed: technical strength and positive media coverage on international small-cap value performance support upside, but overbought RSI levels and missing financial metrics pose risks. Investors should weigh the ETF's exposure to developed markets outside the U.S. against potential volatility from commodity sectors, as noted in recent analysis.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
